Drug intelligence / Profile preview

ZM-014

Development stage: Unknown
Lead developer: Zumutor Biologics
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

ZM-014 is a monoclonal antibody drug candidate developed by Zumutor Biologics. It is designed to target natural killer (NK) cell receptors and exerts its effect through antibody-dependent cell-mediated cytotoxicity (ADCC). The primary therapeutic focus for ZM-014 is lymphoma, with potential applications in other neoplastic, immune system, and hemic/lymphatic diseases. As of the latest updates, the drug remains in the discovery phase of development and has not entered clinical trials or received regulatory approval[1][2][4][5].

Targets

NCR2 (Natural cytotoxicity triggering receptor 2)

Beyond the preview

Go deeper on ZM-014.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ZM-014.

Explore the full profile